Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (380)	12/1/1998 12:26:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

Aventis will possess one of the largest R&D budgets in the industry – 1997 pro forma investments of about $2.5 billion –and a wide range of emerging technologies, particularly in functional genomics, combinatorial chemistry, high-throughput screening, immunology and gene therapy. This combination of resources and expertise will provide the company with an outstanding foundation for long-term growth. Okay, now send some of that budget Ariad's way. The press release suggests that streamlining means job cuts in their distribution network etc...hopefully R&D is increased. Will hunt around on RP's website, see if they have anything like Hoechst-Ariad Genomics. Trades...sold 2k shares in mid 2's, bought back under $2, pretty sweet. I hope we have seen the lows now that the floorless convertible news has been released (fyi, I never read the filings, and I don't know for sure whether that was floorless convertible...but it did seem to weigh on the stock for awhile there). --MM